A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Status:
Recruiting
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to
standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.